Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonatan Salzer

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Trials|June 16, 2022
Internet-based vestibular rehabilitation versus standard care after acute onset vertigo: a study protocol for a randomized controlled trialSolmaz Surano, Helena Grip, Fredrik Öhberg, et al.
Neurology|October 21, 2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacyJonatan Salzer, Rasmus Svenningsson, Peter Alping, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2020
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerationsAngelo Ghezzi, Brenda Banwell, Amit Bar-Or, et al.
JAMA Neurology|October 8, 2019
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesGustavo Luna, Peter Alping, Joachim Burman, et al.
Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 9, 2023
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapyElisa Longinetti, Simon Englund, Joachim Burman, et al.
European Journal of Neurology|February 20, 2024
Rituximab treatment in pediatric-onset multiple sclerosisMarkus Breu, Fredrik Sandesjö, Ruxandra-Iulia Milos, et al.
Multiple Sclerosis and Related Disorders|January 5, 2023
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohortSimon Englund, Marie Kierkegaard, Joachim Burman, et al.
Annals of Neurology|June 26, 2024
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with RituximabFredrik Piehl, Peter Alping, Suvi Virtanen, et al.
Annals of Clinical and Translational Neurology|August 22, 2022
COVID-19 clinical outcomes and DMT of MS patients and population-based controlsElisa Longinetti, Hannah Bower, Kyla A McKay, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Trials|June 16, 2022
Internet-based vestibular rehabilitation versus standard care after acute onset vertigo: a study protocol for a randomized controlled trialSolmaz Surano, Helena Grip, Fredrik Öhberg, et al.
Neurology|October 21, 2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacyJonatan Salzer, Rasmus Svenningsson, Peter Alping, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2020
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerationsAngelo Ghezzi, Brenda Banwell, Amit Bar-Or, et al.
JAMA Neurology|October 8, 2019
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesGustavo Luna, Peter Alping, Joachim Burman, et al.
Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 9, 2023
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapyElisa Longinetti, Simon Englund, Joachim Burman, et al.
European Journal of Neurology|February 20, 2024
Rituximab treatment in pediatric-onset multiple sclerosisMarkus Breu, Fredrik Sandesjö, Ruxandra-Iulia Milos, et al.
Multiple Sclerosis and Related Disorders|January 5, 2023
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohortSimon Englund, Marie Kierkegaard, Joachim Burman, et al.
Annals of Neurology|June 26, 2024
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with RituximabFredrik Piehl, Peter Alping, Suvi Virtanen, et al.
Annals of Clinical and Translational Neurology|August 22, 2022
COVID-19 clinical outcomes and DMT of MS patients and population-based controlsElisa Longinetti, Hannah Bower, Kyla A McKay, et al.
Pageof 5